- More than two-thirds of the studied pediatric patients with chronic myeloid leukemia (CML) experienced molecular relapse after imatinib discontinuation.
- These findings contrast with those of the adult STIM and EURO-SKI studies.
Why this matters
- Study data in adults with CML may have biased decisions for TKI discontinuation in pediatric patients.
- STOP IMAPED study to investigate effects of imatinib discontinuation in 14 pediatric patients with CML who sustained deep molecular remission (DMR) for ≥2 years.
- All patients had achieved DMR at a median of 16 (range, 6-91) months.
- Median age at discontinuation, 14 (range, 9-23) years.
- Data for years 2015, 2016 were sourced from the International Paediatric CML (I-CML-ped) study.
- Funding: None disclosed.
- Median follow-up, 105 (range, 51-183) months.
- 10/14 patients experienced molecular relapse at a median of 3 (range, 1-6) months after imatinib discontinuation; 7 resumed imatinib, 3 initiated dasatinib.
- All 10 patients regained DMR at a median of 8.5 (range, 1-34) months.
- At the time of analysis, all patients were alive, there were no cases of progression to advanced phase.
- 28.6% probability of maintaining DMR at 6 months after discontinuation.
- Univariate analysis identified no significant predictors of sustained DMR.
- Retrospective data; limited sample size.